Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Working Capital Changes: 2020-2025

Historic Other Working Capital Changes for InMed Pharmaceuticals (INM) over the last 6 years, with Jun 2025 value amounting to -$429,880.

  • InMed Pharmaceuticals' Other Working Capital Changes rose 60.47% to -$129,992 in Q3 2025 from the same period last year, while for Sep 2025 it was -$231,005, marking a year-over-year increase of 47.89%. This contributed to the annual value of -$429,880 for FY2025, which is 8.17% down from last year.
  • Per InMed Pharmaceuticals' latest filing, its Other Working Capital Changes stood at -$429,880 for FY2025, which was down 8.17% from -$397,422 recorded in FY2024.
  • In the past 5 years, InMed Pharmaceuticals' Other Working Capital Changes ranged from a high of $823,172 in FY2021 and a low of -$429,880 during FY2025.
  • For the 3-year period, InMed Pharmaceuticals' Other Working Capital Changes averaged around -$417,959, with its median value being -$426,575 (2023).
  • Per our database at Business Quant, InMed Pharmaceuticals' Other Working Capital Changes spiked by 550.42% in 2021 and then tumbled by 123.73% in 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Other Working Capital Changes (Yearly) stood at $823,172 in 2021, then plummeted by 123.16% to -$190,661 in 2022, then plummeted by 123.73% to -$426,575 in 2023, then grew by 6.83% to -$397,422 in 2024, then declined by 8.17% to -$429,880 in 2025.